ArticleHuman pathology2026
Prognostic relevance and molecular correlates of Claudin-1 expression in pancreatic neuroendocrine tumors.
Article in Human pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic neuroendocrine tumors (pNETs) are biologically heterogeneous neoplasms with variable clinical outcomes. Current prognostic assessment relies largely on mitotic count and Ki-67 index, which may be affected by intratumoral heterogeneity and sampling bias. Additional biomarkers are therefore needed to refine risk stratification and characterize aggressive disease biology. Here, we investigated the prognostic and biological significance of Claudin-1 (CLDN1), a tight junction protein implicated in epithelial tumor progression. CLDN1 expression was assessed by immunohistochemistry in 67 surgically resected pNETs using tissue microarrays. A data-driven cutoff (H-score >50) identified a CLDN1-high subset associated with significantly shorter disease-specific survival (p = 0.009) and adverse clinicopathologic features. To define the molecular programs underlying CLDN1 overexpression, we analyzed RNA sequencing profiles from 22 tumors matched for key clinical variables by propensity score matching. CLDN1-high tumors showed attenuation of endocrine lineage markers and enrichment of exocrine and fetal ductal transcriptional programs. Cell-of-origin deconvolution further revealed a shift from endocrine alpha/beta-cell identity toward ductal or acinar-like states. Transcriptomic clustering demonstrated partial convergence between CLDN1-high pNETs and pancreatic ductal adenocarcinoma profiles. In addition, CLDN1-high tumors exhibited activation of epithelial-mesenchymal transition, HIPPO signaling, and immune-related pathways, together with increased stromal and immune cell infiltration. Collectively, our findings identify CLDN1 as a marker of a biologically distinct and clinically aggressive pNETs subset characterized by dedifferentiation, lineage plasticity, and tumor microenvironment remodeling, supporting further evaluation of CLDN1 as a candidate prognostic biomarker and potential therapeutic target in pNETs.
Indexed as
Identifiers
42379528What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.